{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:45:38Z","timestamp":1781887538949,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jim.2025.113917","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T23:35:03Z","timestamp":1753745703000},"page":"113917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of a novel anti-PEG antibody assay enabling investigation of potential immunogenicity triggered by the PEG moiety of biotherapeutics"],"prefix":"10.1016","volume":"543","author":[{"given":"Lisa","family":"Dyleski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Seletskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Walus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Caiazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Baltrukonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lepsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jim.2025.113917_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/wnan.1157","article-title":"Recent advances in stealth coating of nanoparticle drug delivery systems","volume":"4","author":"Amoozgar","year":"2012","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jim.2025.113917_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112856","article-title":"Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity","volume":"486","author":"Bivi","year":"2020","journal-title":"J. Immunol. Methods"},{"issue":"10","key":"10.1016\/j.jim.2025.113917_bb0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4155\/bio-2020-0222","article-title":"Critical reagent characterization and re-evaluation to ensure long-term stability: two case studies","volume":"13","author":"Caiazzo","year":"2021","journal-title":"Bioanalysis"},{"issue":"21","key":"10.1016\/j.jim.2025.113917_bb0020","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"issue":"6","key":"10.1016\/j.jim.2025.113917_bb0025","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1208\/s12248-015-9799-4","article-title":"Development of a generic anti-PEG antibody assay using BioScale\u2019s acoustic membrane MicroParticle technology","volume":"17","author":"Dong","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2025.113917_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112669","article-title":"A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum","volume":"474","author":"Ehlinger","year":"2019","journal-title":"J. Immunol. Methods"},{"issue":"8","key":"10.1016\/j.jim.2025.113917_bb0035","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.jim.2025.113917_bb0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jim.2025.113917_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4155\/bio-2023-0196","article-title":"A singlicate immunogenicity method to detect anti-polyethylene glycol antibodies: pre- and post-dose of PEGylated therapies","volume":"16","author":"Jyamubandi","year":"2024","journal-title":"Bioanalysis"},{"issue":"15","key":"10.1016\/j.jim.2025.113917_bb0050","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4155\/bio.15.112","article-title":"Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples","volume":"7","author":"Krishna","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jim.2025.113917_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-61779-151-2_8","article-title":"Covalent conjugation of poly(ethylene glycol) to proteins and peptides: strategies and methods","volume":"751","author":"Mero","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jim.2025.113917_bb0060","series-title":"Clinical Aspects of Immunology","author":"P. G. H. Gell RRAC.","year":"1963"},{"issue":"3","key":"10.1016\/j.jim.2025.113917_bb0065","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.jim.2025.113917_bb0070","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/bc100067t","article-title":"Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies","volume":"21","author":"Su","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"1\u20132","key":"10.1016\/j.jim.2025.113917_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2010.03.012","article-title":"Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics","volume":"357","author":"Tatarewicz","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2025.113917_bib96","series-title":"Immunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti-Drug Antibody Detection. Guidance for Industry","year":"2019"},{"issue":"4","key":"10.1016\/j.jim.2025.113917_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1208\/s12248-020-00462-z","article-title":"Development of a highly specific anti-drug antibody assay in support of a nanoparticle-based therapeutic","volume":"22","author":"Wang","year":"2020","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.jim.2025.113917_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.jim.2025.113917_bb0090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"16","key":"10.1016\/j.jim.2025.113917_bb0095","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1021\/acs.analchem.7b02447","article-title":"Sensitive and quantitative detection of anti-poly(ethylene glycol) (PEG) antibodies by Methoxy-PEG-coated surface Plasmon resonance sensors","volume":"89","author":"Zhang","year":"2017","journal-title":"Anal. Chem."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925001176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925001176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:16:47Z","timestamp":1779859007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175925001176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"alternative-id":["S0022175925001176"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2025.113917","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel anti-PEG antibody assay enabling investigation of potential immunogenicity triggered by the PEG moiety of biotherapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2025.113917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113917"}}